TY - JOUR
T1 - Time course of IL-6 expression in experimental CNS ischemia
AU - Clark, Wayne M.
AU - Rinker, Lisa G.
AU - Lessov, Nikola S.
AU - Hazel, Kristin
AU - Eckenstein, Felix
PY - 1999
Y1 - 1999
N2 - Interleukin-6 (IL-6) appears to be an important modulator of the inflammatory response associated with CNS ischemia. Clinically, IL-6 values obtained in the first week post-stroke have been shown to correlate with infarct size and outcome. In this study we used a focal reversible stroke model to investigate the time course and relationship to outcome of IL-6 production in plasma, brain and CSF. Reversible middle cerebral artery occlusion or sham surgery was produced in 50 adult Swiss Webster mice by advancing an 8-0 filament into the internal carotid artery for 2 h (sham 1 min). At 3, 6, 12, 24, and 72 h (8 each ischemia; 2 each sham) groups of animals were evaluated on a 28 point clinical scale, blood and CSF obtained, and the brains were evaluated for infarct volume and IL-6 mRNA levels. Serum levels of IL-6 (ELISA mean ± SD; undetectable in controls) overall sham group, 102 ± 87; 3 h, 908 ± 494 * pg ml-1; 6 h, 1079 ± 468 * pg ml- 1; 12 h, 980 ± 221 * pg ml-1; 24 h, 320 ± 314 * pg ml-1; 72 h, 20 ± 30 * pg ml-1 (* p < 0.05 to sham). CSF levels (ELISA) overall sham group, 10 ± 18; 3 h, 379 ± 210 * pg ml-1; 6 h, 157 ± 61 * pg ml-1; 12 h, 136 ± 88 * pg ml-1; 24 h, 127 ± 99 pg ml-1; 72 h, 72 ± 9 * pg ml- 1 (* p ≤ 0.05 to sham). Brain IL-6 mRNA levels overall sham group, 20; 3 h, 480; 6 h, 599; 12 h, 7960; 24 h, 20267; 72 h, 0. There was an overall R2 of 0.20 between plasma and CSF IL-6. There was an overall R2 of 0.13 and 0.20 between infarct size and serum and CSF IL-6 level respectively, and an overall R2 of 0.10 and 0.17 between neurologic function and serum and CSF IL-6 level respectively. These findings confirm that IL-6 values increase following CNS ischemia with peak serum and CSF levels occurring before brain values. CSF IL-6 levels had a stronger correlation with neurologic function and infarct size than serum.
AB - Interleukin-6 (IL-6) appears to be an important modulator of the inflammatory response associated with CNS ischemia. Clinically, IL-6 values obtained in the first week post-stroke have been shown to correlate with infarct size and outcome. In this study we used a focal reversible stroke model to investigate the time course and relationship to outcome of IL-6 production in plasma, brain and CSF. Reversible middle cerebral artery occlusion or sham surgery was produced in 50 adult Swiss Webster mice by advancing an 8-0 filament into the internal carotid artery for 2 h (sham 1 min). At 3, 6, 12, 24, and 72 h (8 each ischemia; 2 each sham) groups of animals were evaluated on a 28 point clinical scale, blood and CSF obtained, and the brains were evaluated for infarct volume and IL-6 mRNA levels. Serum levels of IL-6 (ELISA mean ± SD; undetectable in controls) overall sham group, 102 ± 87; 3 h, 908 ± 494 * pg ml-1; 6 h, 1079 ± 468 * pg ml- 1; 12 h, 980 ± 221 * pg ml-1; 24 h, 320 ± 314 * pg ml-1; 72 h, 20 ± 30 * pg ml-1 (* p < 0.05 to sham). CSF levels (ELISA) overall sham group, 10 ± 18; 3 h, 379 ± 210 * pg ml-1; 6 h, 157 ± 61 * pg ml-1; 12 h, 136 ± 88 * pg ml-1; 24 h, 127 ± 99 pg ml-1; 72 h, 72 ± 9 * pg ml- 1 (* p ≤ 0.05 to sham). Brain IL-6 mRNA levels overall sham group, 20; 3 h, 480; 6 h, 599; 12 h, 7960; 24 h, 20267; 72 h, 0. There was an overall R2 of 0.20 between plasma and CSF IL-6. There was an overall R2 of 0.13 and 0.20 between infarct size and serum and CSF IL-6 level respectively, and an overall R2 of 0.10 and 0.17 between neurologic function and serum and CSF IL-6 level respectively. These findings confirm that IL-6 values increase following CNS ischemia with peak serum and CSF levels occurring before brain values. CSF IL-6 levels had a stronger correlation with neurologic function and infarct size than serum.
KW - CNS ischemia
KW - Infarct size
KW - Inflammatory response
KW - Interleukin-6
KW - Neurologic function
UR - http://www.scopus.com/inward/record.url?scp=0032915929&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032915929&partnerID=8YFLogxK
U2 - 10.1080/01616412.1999.11740933
DO - 10.1080/01616412.1999.11740933
M3 - Article
C2 - 10319338
AN - SCOPUS:0032915929
SN - 0161-6412
VL - 21
SP - 287
EP - 292
JO - Neurological Research
JF - Neurological Research
IS - 3
ER -